Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Thompson

Showing results (591-600 of 637) with videos related to

Pageof 64
Sort By:
ACS Central Science|December 31, 2025
Gluebodies Offer a Route To Improve Crystal Reliability and Diversity through Transferable Nanobody Mutations That Introduce Constitutive Close ContactsMingda Ye, Mpho Makola, Mark W Richards, et al.
Ebiomedicine|September 18, 2024
Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemiaWeronika E Borek, Luis Nobre, S Federico Pedicona, et al.
Frontiers in Psychiatry|June 30, 2020
Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical TrialMaximus Berger, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Research|December 19, 2018
Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trialLuke K Bolt, G Paul Amminger, John Farhall, et al.
Early Intervention in Psychiatry|September 7, 2020
Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosisAlison McLaverty, Kelly A Allott, Maximus Berger, et al.
Psychological Medicine|March 12, 2025
Characterising symptomatic substates in individuals on the psychosis continuum: a hidden Markov modelling approachIsabelle Scott, Emmeke Aarts, Cassandra Wannan, et al.
Bjpsych Open|September 8, 2022
Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trialNicholas Cheng, Alison McLaverty, Barnaby Nelson, et al.
Brain, Behavior, and Immunity|October 8, 2021
The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trialSubash Raj Susai, David Mongan, Colm Healy, et al.
Behaviour Research and Therapy|December 3, 2019
Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trialJessica A Hartmann, Stefanie J Schmidt, Patrick D McGorry, et al.
The Lancet. Psychiatry|May 15, 2022
The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and AustraliaAndrew I Gumley, Simon Bradstreet, John Ainsworth, et al.
Pageof 64

Showing results (591-600 of 637) with videos related to

Sort By:
Pageof 64
ACS Central Science|December 31, 2025
Gluebodies Offer a Route To Improve Crystal Reliability and Diversity through Transferable Nanobody Mutations That Introduce Constitutive Close ContactsMingda Ye, Mpho Makola, Mark W Richards, et al.
Ebiomedicine|September 18, 2024
Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemiaWeronika E Borek, Luis Nobre, S Federico Pedicona, et al.
Frontiers in Psychiatry|June 30, 2020
Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical TrialMaximus Berger, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Research|December 19, 2018
Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trialLuke K Bolt, G Paul Amminger, John Farhall, et al.
Early Intervention in Psychiatry|September 7, 2020
Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosisAlison McLaverty, Kelly A Allott, Maximus Berger, et al.
Psychological Medicine|March 12, 2025
Characterising symptomatic substates in individuals on the psychosis continuum: a hidden Markov modelling approachIsabelle Scott, Emmeke Aarts, Cassandra Wannan, et al.
Bjpsych Open|September 8, 2022
Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trialNicholas Cheng, Alison McLaverty, Barnaby Nelson, et al.
Brain, Behavior, and Immunity|October 8, 2021
The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trialSubash Raj Susai, David Mongan, Colm Healy, et al.
Behaviour Research and Therapy|December 3, 2019
Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trialJessica A Hartmann, Stefanie J Schmidt, Patrick D McGorry, et al.
The Lancet. Psychiatry|May 15, 2022
The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and AustraliaAndrew I Gumley, Simon Bradstreet, John Ainsworth, et al.
Pageof 64